{"publication_id":"08b65e1f-64fd-4028-b8a6-b572e628a8f0","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}